Depression
Conditions
Keywords
Depression, Smartphone, Behavioural activation, Mindfulness
Brief summary
The objective is to test the effects of a smartphone-delivered behavioural activation treatment. Also, a moderator analysis of low and high severity of depressive symptoms will be made. We expect the behavioural activation intervention to be superior to the mindfulness intervention for the participants suffering from high severity of depressive symptoms - and the mindfulness intervention to be better or at least as good as the behavioural activation intervention for the participants suffering from low severity of depressive symptoms.
Detailed description
Major depression is expected to be the disorder with the highest disease burden in high-income countries by the year 2030. The efficacy of behavioural activation in the treatment of major depressive disorders has been established in a number of studies over the last four decades. Furthermore, behavioural activation is an intervention that can largely benefit from the use of new mobile technologies (e.g. smartphones). One important feature of mobile technology is the possibility for the therapist to reach the patient between sessions and thus create direct incentives for behavioural activation in everyday life. Therefore, developing smartphone-based behavioural activation interventions might be a way to develop a cost-effective treatment for people suffering from major depressive disorders.
Interventions
BEHAVIORALSmartphone delivered BA
A 8 week behavioural activation therapy delivered through smartphone
A 8 week mindfulness intervention delivered through smartphone
Sponsors
Linkoeping University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* depressive symptoms according to DSM-IV * have access to the Internet and a smartphone * have good knowledge of the Swedish language
Exclusion criteria
* recent (during last 6 weeks) change in psychiatric medication * presently in any other psychological treatment * severe depression * suicidal ideation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patient Health Questionnaire (PHQ-9)- Change from baseline | Two weeks pre treatment, two weeks post treatment, six months and 12 months post treatment | Change from baseline in anxiety symptoms two weeks post treatment, at six months and at 12 months post treatment. |
| Beck Depression Inventory (BDI)- Change from baseline | Two weeks pre treatment, two weeks post treatment, six months and 12 months post treatment | Change from baseline in anxiety symptoms two weeks post treatment, at six months and at 12 months post treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of Life Inventory (QOLI)- Change from baseline | Two weeks pre treatment, two weeks post treatment, six months and 12 months post treatment | Change from baseline in anxiety symptoms two weeks post treatment, at six months and at 12 months post treatment. |
| Acceptance & Action Questionnaire (AAQ)- Change from baseline | Two weeks pre treatment, two weeks post treatment, six months and 12 months post treatment | Change from baseline in anxiety symptoms two weeks post treatment, at six months and at 12 months post treatment. |
| Beck Anxiety Inventory (BAI)- Change from baseline | Two weeks pre treatment, two weeks post treatment, six months and 12 months post treatment | Change from baseline in anxiety symptoms two weeks post treatment, at six months and at 12 months post treatment. |
| Trimbos and iMTA questionnaire on Costs associated with Psychiatric illness (TIC-P)- Change from baseline | Two weeks pre treatment and at six months post treatment. | Change from baseline in health cost burden and at six months post treatment. |
Countries
Sweden
Outcome results
None listed